

RA Management

Drug response variability

RA Burden and Drug Response Variability

A study by Wipfler and colleagues explored disease burden in RA patients based on shared epitope and ACPA status. Findings showed higher comorbidity burden in ACPA-negative individuals and differences in disease activity, healthcare usage, and DMARD use between ACPA-positive and ACPA-negative patients. Response to abatacept was linked to ACPA status, but neither ACPA nor shared epitope status predicted responses to TNF or JAK inhibitors.

References

1 Wipfler et al. RA Burden of disease and Drug Response in patients with rheumatoid arthritis. . . Feb 2026. The Journal of Rheumatology

Old

Hydroxychloroquine
Sulfasalazine

Standard

Methotrexate
Leflunomide

New

Enbrel (Etanercept)
Humira (Adalimumab)
Cimzia (Certolizumab)
Simponi (Golimumab)
Remicade (Infliximab)

Orencia (Abatacept)

Rituxan (Rituximab)

Actemra (Tocilizumab)

Xeljanz (Tofacitinib)
Rinvoq (Upadacitinib)
Olumiant (Baricitinib)